Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
14 - Myelodysplastic/myeloproliferative neoplasm overlap syndromes
Published online by Cambridge University Press: 05 March 2016
Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Managing Myeloproliferative NeoplasmsA Case-Based Approach, pp. 120 - 128Publisher: Cambridge University PressPrint publication year: 2016
References
Swerdlow, S, Campo, E, Harris, NL, Jaffe, E, Pileri, S, Stein, H. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer, Lyon, France; 2008.Google Scholar
Flach, J, Dicker, F, Schnittger, S, Kohlmann, A, Haferlach, T, Haferlach, C. Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis. Haematologica. 2010;95(3):518–19. PubMed PMID: 19903679. Pubmed Central PMCID: 2833086.CrossRefGoogle ScholarPubMed
Visconte, V, Rogers, HJ, Singh, J, Barnard, J, Bupathi, M, Traina, F, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood. 2012;120(16):3173–86. PubMed PMID: 22826563. Pubmed Central PMCID: 3476536.CrossRefGoogle ScholarPubMed
Strom, SS, Gu, Y, Gruschkus, SK, Pierce, SA, Estey, EH. Risk factors of myelodysplastic syndromes: a case-control study. Leukemia. 2005;19(11):1912–18. PubMed PMID: 16167059.CrossRefGoogle ScholarPubMed
Surveillance, Epidemiology, and End Results (SEER) Program (2000–2012) 2014 [updated April 2014; cited 2014 August 18, 2014]. Available from: http://www.seer.cancer.gov.Google Scholar
Osca-Gelis, G, Puig-Vives, M, Saez, M, Gallardo, D, Lloveras, N, Marcos-Gragera, R. Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain. Haematologica. 2013;98(8):e95–7. PubMed PMID: 23812933. Pubmed Central PMCID: 3729892.CrossRefGoogle ScholarPubMed
Greenberg, P, Cox, C, LeBeau, MM, Fenaux, P, Morel, P, Sanz, G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–88. PubMed PMID: 9058730.CrossRefGoogle ScholarPubMed
Greenberg, PL, Tuechler, H, Schanz, J, Sanz, G, Garcia-Manero, G, Sole, F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–65. PubMed PMID: 22740453.CrossRefGoogle ScholarPubMed
Onida, F, Kantarjian, HM, Smith, TL, Ball, G, Keating, MJ, Estey, EH, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002;99(3):840–9. PubMed PMID: 11806985.CrossRefGoogle ScholarPubMed
Such, E, Germing, U, Malcovati, L, Cervera, J, Kuendgen, A, Della Porta, MG, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15):3005–15. PubMed PMID: 23372164.CrossRefGoogle ScholarPubMed
Calvo, X, Nomdedeu, M, Costa, D, Pereira, A, Martínez, N, Esteve, J, et al. Evaluation of two prognostic scoring systems for chronic myelomonocytic leukemia (CMML): CMML-specific Prognostic Scoring System (CPSS) and MD Anderson Prognostic Score (MDAPS) in a series of 122 cases of de novo CMML. Blood. 2013;122(21):2810.CrossRefGoogle Scholar
Patnaik, MM, Padron, E, LaBorde, RR, Lasho, TL, Finke, CM, Hanson, CA, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013;27(7):1504–10. PubMed PMID: 23531518.Google ScholarPubMed
Itzykson, R, Kosmider, O, Renneville, A, Gelsi-Boyer, V, Meggendorfer, M, Morabito, M, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31(19):2428–36. PubMed PMID: 23690417.CrossRefGoogle ScholarPubMed
Patnaik, MM, Itzykson, R, Lasho, TL, Kosmider, O, Finke, CM, Hanson, CA, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014;28(11):2206–12. PubMed PMID: 24695057.CrossRefGoogle ScholarPubMed
Wattel, E, Guerci, A, Hecquet, B, Economopoulos, T, Copplestone, A, Mahe, B, et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. Blood. 1996;88(7):2480–7. PubMed PMID: 8839839.CrossRefGoogle ScholarPubMed
Braun, T, Itzykson, R, Renneville, A, de Renzis, B, Dreyfus, F, Laribi, K, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood. 2011;118(14):3824–31. PubMed PMID: 21828134.CrossRefGoogle ScholarPubMed
Lyons, RM, Cosgriff, TM, Modi, SS, Gersh, RH, Hainsworth, JD, Cohn, AL, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol. 2009;27(11):1850–6. PubMed PMID: 19255328.CrossRefGoogle ScholarPubMed
Meggendorfer, M, Roller, A, Haferlach, T, Eder, C, Dicker, F, Grossmann, V, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood. 2012;120(15):3080–8.CrossRefGoogle ScholarPubMed
Sorror, ML. How I assess comorbidities before hematopoietic cell transplantation. Blood. 2013;121(15):2854–63.CrossRefGoogle Scholar
Eissa, H, Gooley, TA, Sorror, ML, Nguyen, F, Scott, BL, Doney, K, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transplant. 2011;17(6):908–15. PubMed PMID: 20932924. Pubmed Central PMCID: 3100432.CrossRefGoogle ScholarPubMed
Park, S, Labopin, M, Yakoub-Agha, I, Delaunay, J, Dhedin, N, Deconinck, E, et al. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Eur J Haematol. 2013;90(5):355–64. PubMed PMID: 23320648.CrossRefGoogle ScholarPubMed
Liu, Y, Tabarroki, A, Visconte, V, Hasrouni, E, Bupathi, M, Hamilton, BK, et al. A prognostic scoring system for unclassifiable MDS and MDS/MPN. ASH Annual Meeting Abstracts. 2012 November 16, 2012;120(21):1701.Google Scholar
Caceres, G, McGraw, K, Yip, BH, Pellagatti, A, Johnson, J, Zhang, L, et al. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proc Natl Acad Sci U. S. A. 2013;110(40):16127–32. PubMed PMID: 24043769. Pubmed Central PMCID: 3791697.CrossRefGoogle ScholarPubMed
Visconte, V, Makishima, H, Jankowska, A, Szpurka, H, Traina, F, Jerez, A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia. 2012;26(3):542–5. PubMed PMID: 21886174.CrossRefGoogle ScholarPubMed
Savona, MR, Malcovati, L, Komrokji, R, Tiu, RV, Mughal, TI, Orazi, A, et al. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood. 2015;125(12):1857–65. PubMed PMID: 25624319.CrossRefGoogle Scholar